Pulse Biosciences Inc - Asset Resilience Ratio
Pulse Biosciences Inc (PLSE) has an Asset Resilience Ratio of 0.00% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PLSE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2021)
This chart shows how Pulse Biosciences Inc's Asset Resilience Ratio has changed over time. See Pulse Biosciences Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Pulse Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Pulse Biosciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Pulse Biosciences Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Pulse Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Pulse Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for Pulse Biosciences Inc (2015–2021)
The table below shows the annual Asset Resilience Ratio data for Pulse Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $54.25 Million | -- |
| 2020-12-31 | 19.40% | $8.01 Million | $41.29 Million | -24.73pp |
| 2019-12-31 | 44.13% | $18.50 Million | $41.91 Million | +32.13pp |
| 2018-12-31 | 12.00% | $8.48 Million | $70.64 Million | -57.61pp |
| 2017-12-31 | 69.62% | $34.68 Million | $49.82 Million | +15.25pp |
| 2016-12-31 | 54.37% | $14.31 Million | $26.31 Million | -45.50pp |
| 2015-12-31 | 99.87% | $14.31 Million | $14.33 Million | -- |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Ca… Read more